Patents by Inventor Kyoung-Ho PYO

Kyoung-Ho PYO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240261403
    Abstract: The present specification provides not only an antigen-specific T cell receptor but also a nucleic acid, a vector, and an immune cell comprising the T cell receptor, and a method using same.
    Type: Application
    Filed: October 7, 2021
    Publication date: August 8, 2024
    Applicant: DAAN BIOTHERAPEUTICS CO., LTD.
    Inventors: Byoung Chul CHO, Kyoung Ho PYO, Jae Hwan KIM, Yeong Seon BYEON, Young Seob KIM, Chun Feng XIN
  • Publication number: 20210292710
    Abstract: There is provided a method for enhancing immune function of an immune cell, and an immune cell line produced using the method. A method for enhancing immune function of an immune cell according to an exemplary embodiment of the present invention includes: treating immune cells with a PI3K inhibitor to activate AKT/mTOR downstream signal ex vivo; and culturing the immune cells treated with the PI3K inhibitor such that a lowered AKT level rebounds.
    Type: Application
    Filed: March 27, 2020
    Publication date: September 23, 2021
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Byoung Chul CHO, Kyoung-Ho PYO, Chang Gon KIM, Sung-Eun KIM, Jae Hwan KIM, Yeongseon BYEON
  • Patent number: 10688085
    Abstract: Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: June 23, 2020
    Assignees: UNIVERSITY-INDUSTRY FOUNDATION, YONSEI UNIVERSITY, JEUK CO., LTD.
    Inventors: Kyoung-Je Cho, Byoung Chul Cho, Mi-Ran Yun, Kyoung-Ho Pyo, Han Na Kang, Hun-Mi Choi
  • Publication number: 20190046514
    Abstract: Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.
    Type: Application
    Filed: January 13, 2017
    Publication date: February 14, 2019
    Inventors: Kyoung-Je CHO, Byoung Chul CHO, Mi-Ran YOON, Kyoung-Ho PYO, Han Na KANG, Hun-Mi CHOI